Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

BPC-157 Potential On Angiogenesis and Cell Survival

BPC-157 Potential On Angiogenesis and Cell Survival Dec 29, 2024 Figure 1: BPC-157 chemical structure Research BPC-157 Potential On Angiogenesis BPC-157 is posited to support cellular survival and regeneration primarily by modifying angiogenesis. There are sev

By Recovery & Performance Peptides Editorial Team

BPC-157 Potential On Angiogenesis and Cell Survival

Dec 29, 2024

Figure 1: BPC-157 chemical structure

Research

BPC-157 Potential On Angiogenesis

BPC-157 is posited to support cellular survival and regeneration primarily by modifying angiogenesis. There are several potential pathways for the peptide to do so:

BPC-157 may modify one of the major classes of receptors that stimulate angiogenesis, namely the Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). Research by Hsieh et al. suggests that BPC-157 may up-regulate the expression of VEGFR2 in endothelial cells, as indicated by observed increases in both VEGFR2 mRNA and protein levels in cultured endothelial cells. (2) This up-regulation might facilitate a more robust VEGF-A and VEGFR2 interaction, which is crucial for angiogenesis. Additionally, BPC-157 appears to promote the internalization of VEGFR2, a process that is typically associated with VEGFR2 activation. The internalization of VEGFR2 by BPC-157 may lead to the activation of downstream signaling pathways, specifically the VEGFR2-Akt-eNOS cascade. Activation of this pathway is potentially significant for angiogenesis, as it may support endothelial cell survival, proliferation, and the formation of new blood vessels.

By activating the eNOS enzyme, the peptide appears to upregulate NO synthesis, which is a major vasodilator fundamentally involved in vascular function and angiogenesis. Moreover, the peptide appears to modulate the NO pathway, which is fundamentally involved in vascular function and angiogenesis. Specifically, BPC-157 may interact with endothelial cells, providing endothelium protection by possibly maintaining NO bioavailability. This interaction might facilitate the stabilization of blood vessels and support new blood vessel formation, a process essential for angiogenesis. Sikiric et al. have commended that the peptide may counteract the actions of NO synthase (NOS) inhibitors like L-NAME, which suggests that BPC-157 might help sustain NO production under conditions where it is otherwise diminished. (3) This maintenance of NO levels might prove critical in ensuring adequate blood flow and vessel integrity during the angiogenic process.

Furthermore, BPC-157 is believed to influence the expression of the early growth response 1 (egr-1) gene, which is responsible for the generation of cytokines and growth factors that are pivotal in the angiogenic process.(3) Researchers such as Tkalcević et al. suggest that by stimulating egr-1, BPC-157 may support the production of factors that promote endothelial cell proliferation and migration, thereby potentially fostering the formation of new blood vessels. (4) Furthermore, the researchers posited that the activation of “EGR-1 induces cytokine and growth factor generation and early extracellular matrix (collagen) formation,” which further elucidates the mechanisms behind the regenerative potential of BPC-157.

BPC-157 Potential On Digestive System Tissues

A study by Luetic et al. suggests that by supporting angiogenesis, BPC-157 may support the recovery and regeneration of digestive system tissues in laboratory conditions.(5) Specifically, BPC-157 may aid in restoring vascular integrity and promoting tissue repair. In addition, BPC-157 appears to potentially mitigate the elevated levels of malondialdehyde (MDA) during experimentally induced oxidative stress. Elevated MDA is posited to be a marker of oxidative stress, which may lead to cellular damage and impede tissue recovery. By possibly attenuating oxidative stress markers, BPC-157 may help protect gastric and duodenal cells from reactive oxygen species (ROS)-induced cytotoxicity.

Additionally, another study by Sikiric et al. suggests that BPC-157 may also interact with adrenergic and dopaminergic receptors to exert its gastroprotective potential.(6) The peptide’s protective action was reportedly abolished by agents targeting alpha-adrenergic receptors (such as phentolamine and clonidine) and dopaminergic receptors (such as haloperidol), suggesting a potential involvement of these pathways. Furthermore, the protective action was influenced by beta-adrenergic blockers like atenolol and propranolol, depending on the route of BPC-157 administration. This indicates that BPC-157 might modulate catecholamine release and dopamine receptor activity, contributing to its ability to protect against gastrointestinal lesions under stress conditions.

BPC-157 Potential On Neuron Survival

BPC-157 may exhibit neuroprotective actions on nerve cells. Research by Tohyama et al. suggests it might protect peripheral sensory neurons, which are cells responsible for transmitting information like touch and pain to the spinal cord, and potentially promote the regrowth of peripheral nerves following injury. (7) This may include reducing the death of nerve cells, limiting the degradation of the myelin sheath (a lipid-rich layer insulating nerve fibers), and mitigating the formation of cysts (fluid-filled cavities) in the affected nerve tissue. This potential may be based on the ability of BPC-157 to modify the expression of egr-1 and its co-repressor NAB2 (NGFI-A-binding protein-2), which are transcription factors that may influence gene expression patterns during neuronal growth, differentiation, or injury responses.

By interacting with NAB2, studies by Sikiric et al. also suggest that BPC-157 might affect inflammatory responses, thereby modulating inflammation or tissue remodeling.(3) Reductions in harmful inflammatory factors may, in turn, favor neuronal stability and potentially assist in repairing nerve damage. Alterations in gene expression influenced by Egr-1 and NAB2 may also, in uncertain ways, control the production of proteins needed for neuronal growth and differentiation, potentially offering some level of indirect support against injury. Furthermore, studies suggest that by engaging multiple neurotransmitter and signaling systems, including the interplay between serotonergic and dopaminergic pathways, and by potentially influencing GABAergic inhibition, opioid-related analgesia, and inflammatory processes, BPC-157 may ultimately shape a neurochemical environment that encourages neuron survival and nerve tissue regeneration. However, its overall impact remains far from fully understood.

BPC-157 Potential On Connective Tissue Cells

Research by Chang et al. suggests that BPC-157 may influence connective tissue cells and facilitate connective tissue recovery. According to the researchers, BPC-157 appears to possibly support the outgrowth of tendon fibroblasts from tendon explants in laboratory settings, which may indicate a role in promoting the initial stages of tendon regeneration. This peptide may also potentially increase the survival of tendon fibroblasts under oxidative stress conditions, suggesting a protective action that might support cell viability during the healing process. Furthermore, BPC-157 is posited to support the migratory capacity of tendon fibroblasts.

The scientists involved in these studies commented that “BPC 157 markedly increased the in vitro migration of tendon fibroblasts […] as revealed by transwell filter migration assay.” This increased cell migration may be crucial for repopulating the injured tissue model with necessary cellular components. Additionally, BPC-157 may accelerate the spreading of tendon fibroblasts on culture surfaces, which is an essential aspect of cell adhesion and movement within the extracellular matrix.

At the molecular level, the peptide is thought to possibly induce the formation of F-actin, a key component of the cytoskeleton involved in cell movement and structural integrity. This induction of F-actin formation is believed to facilitate better-supported migration and spreading and possibly have a role in activating tendon fibroblasts exposed to BPC-157. Moreover, BPC-157 is suggested to activate the FAK-paxillin signaling pathway. The phosphorylation of FAK and paxillin, which are integral to focal adhesion dynamics and cell motility, might underlie the increased migratory behavior of tendon fibroblasts. This activation may potentially lead to the strengthening of intracellular signaling networks that govern cell movement and interaction with the extracellular matrix. Furthermore, BPC-157 seemed to increase cell survival under oxidative stress induced by hydrogen peroxide (H₂O₂).

NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

References:

Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, Pavlov KH, Petrovic A, Sikiric S, Vranes H, Prtoric A, Zizek H, Durasin T, Dobric I, Staresinic M, Strbe S, Knezevic M, Sola M, Kokot A, Sever M, Lovric E, Skrtic A, Blagaic AB, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021 Jun 29;12:627533. doi: 10.3389/fphar.2021.627533. PMID: 34267654; PMCID: PMC8275860.

Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JS. The therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017 Mar;95(3):323-333. doi: 10.1007/s00109-016-1488-y. Epub 2016 Nov 15. PMID: 27847966.

Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Stambolija V, Zoricic Z, Vrcic H, Sebecic B. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2012;19(1):126-32. doi: 10.2174/092986712803414015. PMID: 22300085.

Tkalcević VI, Cuzić S, Brajsa K, Mildner B, Bokulić A, Situm K, Perović D, Glojnarić I, Parnham MJ. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol. 2007 Sep 10;570(1-3):212-21. doi: 10.1016/j.ejphar.2007.05.072. Epub 2007 Jun 16. PMID: 17628536.

Luetic K, Sucic M, Vlainic J, Halle ZB, Strinic D, Vidovic T, Luetic F, Marusic M, Gulic S, Pavelic TT, Kokot A, Seiwerth RS, Drmic D, Batelja L, Seiwerth S, Sikiric P. Cyclophosphamide induced stomach and duodenal lesions as a NO-system disturbance in rats: L-NAME, L-arginine, stable gastric pentadecapeptide BPC 157. Inflammopharmacology. 2017 Apr;25(2):255-264. doi: 10.1007/s10787-017-0330-7. Epub 2017 Mar 2. PMID: 28255738.

Sikirić P, Mazul B, Seiwerth S, Grabarević Z, Rucman R, Petek M, Jagić V, Turković B, Rotkvić I, Mise S, Zoricić I, Jurina L, Konjevoda P, Hanzevacki M, Gjurasin M, Separović J, Ljubanović D, Artuković B, Bratulić M, Tisljar M, Miklić P, Sumajstorcić J. Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress. Dig Dis Sci. 1997 Mar;42(3):661Doi. doi: 10.1023/a:1018880000644. PMID: 9073154.

Tohyama Y, Sikirić P, Diksic M. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyl-L-tryptophan autoradiographic measurements. Life Sci. 2004 Dec 3;76(3):345-57. doi: 10.1016/j.lfs.2004.08.010. PMID: 15531385.

Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011 Mar;110(3):774-80. doi: 10.1152/japplphysiol.00945.2010. Epub 2010 Oct 28. PMID: 21030672.

Dr. Marinov

Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.

Latest Blog Articles

Thymogen Potential in Immune Cell Regulation

CJC-1295 & Hexarelin Blend Potential for Growth Hormone Signaling Stimulation

Oxytocin Actions On Neuronal Circuits in Different Mammalian Research Models

Kisspeptin 45-54 Peptide Interactions with Hypothalamic and Neuronal Cells

T-31 Peptide Interactions with Cellular Aging, Renewal, and Stress Pathways

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

BPC-157 40s Age Specific Protocol — Dosing & Recovery

Research from the University of Zagreb's Department of Pharmacology found that BPC-157 (Body Protection Compound-157) demonstrates measurably different recovery kinetics in age-stratified trials. Specifically, subjects over 40 showed delayed initial response (7–10 days vs 4–6 days) but sustained healing effects 30–40% longer than younger cohorts. The mechanism involves modulated VEGF (vascular endothelial growth factor) signaling and fibroblast growth factor expression, both of which decline by approximately 1% per year after age 35. The implication: BPC-157 40s age specific protocol design must account for altered baseline physiology. Not just scale dosing linearly. Our team has worked with researchers using peptides across age demographics for over a decade. The gap between doing it right and doing it wrong in your 40s comes down to three things most guides never mention: dose timing relative to circadian cortisol peaks, reconstitution stability at room temperature during travel, and the interplay between BPC-157 and age-related inflammatory cytokine elevation. What is the optimal BPC-157 protocol for individuals in their 40s? The optimal BPC-157 40s age specific protocol involves subcutaneous injection of 300–500mcg daily, administered in the morning to align with peak growth hormone pulsatility. Recovery timelines extend 20–30% compared to protocols for individuals under 35 due to reduced collagen synthesis rates and elevated baseline IL-6 (interleukin-6) levels. Dosing …
SIDE EFFECTS

BPC-157 Side Effects

There is little scientific documentation of BPC-157 side effects in humans, so most potential side effects are extrapolated from preclinical studies and anecdotal reports of human use. The most common side effects appear to be related to the method of administration, which is typically intramuscular or subcutaneous injection. Common side effects of injections include redness, swelling, itching or skin reactions at the injection site. When these reactions are mild, they typically aren't cause for concern. In addition, because BPC-157 is a gastric peptide, there have been some informal reports of digestive side effects like nausea, diarrhea, appetite changes, gas and bloating related to its administration. Dizziness and headaches also have been reported. As an pro-angiogenic agent, it's theoretically possible for BPC-157 to enable cancers to grow. However, not enough is known about this theoretical issue to elucidate a risk-benefit tradeoff and how timing of treatment works into such a tradeoff. For more discussion of this concern, see our article on potential complications of BPC-157. We reiterate that there have been no definitive human studies investigating BPC-157 side effects. BPC-157 administration and dosing should be handled by a researcher who is familiar with BPC-157. Under no circumstances should it be purchased for self-administration or unauthorized experimentation. Researchers may also want to learn more about how BPC-157 affects both erectile dysfunction and cancer.
02

Question drills

Open a question for its connected answer.

01What If I Experience Injection Site Irritation or Bruising?+

Rotate injection points within the target area rather than using the exact same spot daily. Bruising is common in older populations due to reduced capillary integrity and doesn't indicate incorrect technique. Applying light pressure for 30 seconds post-injection reduces hematoma formation. Persistent redness, swelling, or warmth at the injection site suggests contamination or allergic response. Discontinue use and consult a medical professional. Using bacteriostatic water (not sterile water) for reconstitution and ensuring sterile technique (alcohol swab before each injection, never reusing needles) prevents most infection risk.

SOURCE / realpeptides.co ↗
02What If You Don't Have Access to a Laminar Flow Hood for Reconstitution?+

Use a still-air box constructed from a clear plastic storage container with arm holes cut in the sides, thoroughly disinfected with 70% ethanol and allowed to dry for 10 minutes before use. Position the box in a low-traffic area away from air vents. Perform the reconstitution inside the box using full aseptic technique. The still-air environment reduces airborne particulate introduction by 70–80% compared to open bench work.

SOURCE / realpeptides.co ↗
03What If I Want to Use BPC-157 for a Chronic Tendon Injury?+

BPC-157 is not FDA-approved for human use. It remains an investigational compound legally available only for research purposes. If you're considering BPC-157 for a personal tendon issue, understand that you would be using a peptide with no established human safety profile, no standardized dosing guidelines, and no clinical oversight. Animal studies suggest doses in the range of 200–500 mcg daily for a 70 kg human (extrapolated from 10 mcg/kg rodent dosing using allometric scaling), but this is speculative. Not medical guidance. The peptide is typically administered via subcutaneous injection near the injury site, though intramuscular and oral routes have also been studied in animals.

SOURCE / realpeptides.co ↗
04What If I'm Not Seeing Results After Four Weeks at 500mcg Daily?+

Review your reconstitution and storage protocol first. Most 'non-responder' cases trace to degraded peptide, not biological resistance. If storage was correct, assess mechanical load: are you resting the injury enough for angiogenesis and collagen remodeling to occur, or are you continuing high-impact activity that re-injures tissue faster than BPC-157 can facilitate repair? The peptide accelerates healing; it doesn't override continued damage. Finally, verify your source's third-party testing. A vial marketed at 98% purity that actually contains 65% BPC-157 will underperform regardless of dosing discipline.

SOURCE / realpeptides.co ↗
05What If I Wait Longer Than 90 Minutes Between Injections — Is 2–3 Hours Still Effective?+

Partially. BPC-157's angiogenic effects peak at 4 hours and persist for 6–8 hours, so LL-37 administered at 2–3 hours still benefits from enhanced vascularisation. However, LL-37's chemotactic window (the period when recruited neutrophils are actively migrating) lasts only 90–120 minutes. Delaying LL-37 beyond 2 hours means you're introducing immune activation after the peak vascular expansion window, reducing the compounding effect. If dosing logistics require a longer gap, 2 hours is acceptable; beyond 3 hours, you're treating sequentially rather than synergistically.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Preclinical Safety Studies

Comprehensive preclinical safety evaluations of BPC-157 demonstrate a remarkably favorable toxicological profile. Despite wide dose ranges tested (6 μg/kg to 20 mg/kg), multiple administration routes (intramuscular, intraperitoneal, intravenous, oral), and varied dosing frequencies across numerous animal models, no acute lethal dose has been identified. Limit test studies failed to establish an LD50, indicating exceptionally low acute toxicity even at very high doses. Subchronic and chronic toxicity studies extending up to several months of continuous BPC-157 administration reveal no significant organ toxicity, hematological abnormalities, or pathological changes in treated animals compared to controls. Histopathological examination of major organs including liver, kidney, heart, brain, and reproductive tissues shows no treatment-related lesions. Clinical chemistry and hematology parameters remain within normal ranges across dose levels and treatment durations. Reproductive and developmental toxicity studies indicate no adverse effects on fertility, pregnancy outcomes, or offspring development in rodent models exposed to BPC-157. Teratogenicity studies show no increased incidence of congenital abnormalities in offspring of treated animals. However, these preclinical findings do not establish safety for use during human pregnancy, as species differences in placental transfer and fetal metabolism may exist. Standard precautionary principles recommend avoiding use during pregnancy absent compelling medical necessity and informed risk-benefit assessment.

RESEARCH

The Evidence-Based Truth About BPC-157 Cartalax Joint Protocols

Here's the honest answer: the mechanistic rationale for combining BPC-157 and Cartalax is scientifically sound, but calling it a 'proven protocol' overstates the evidence. Rodent tendon studies show BPC-157 works. That part is solid. Cartalax shows mitochondrial benefits in cell culture and aged animal models. Also solid. What we don't have is a single randomized controlled trial in humans testing the combined protocol specifically for joint repair. The 2021 case series from Eastern Europe is observational data with confounding variables. Calling it 'research-backed' is technically accurate because research exists on each peptide individually, but implying the combination has been clinically validated is misleading. The bigger issue: most joint injuries improve with time and rest regardless of intervention. A 2019 meta-analysis in Sports Medicine found that 60–70% of tendinopathies show significant improvement within 12 weeks using only eccentric exercise and load management. No peptides required. If you're running a BPC-157 cartalax protocol joint research study and see 70% improvement rates, you can't attribute that to the peptides without a control group. This is why the protocol remains experimental. It's worth investigating. The mechanisms make sense. But anyone claiming it's a validated treatment is ahead of the evidence.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

BPC-157 Studied Muscle Tear Research: Animal vs Human Evidence

Seiwerth et al. (2018) Rat Achilles tendon tear 10 mcg/kg daily 40% faster healing vs control Increased VEGF and collagen synthesis Surgical injury model. Not spontaneous tear Cha…

Comparison

BPC-157 Studied Leaky Gut: Comparison of Routes & Dosing Strategies

Intraperitoneal Injection 10–100 mcg/kg Indirect. Systemic circulation first Low. Not viable in humans Standard in research but no clinical equivalent Subcutaneous Injection 10–50…

Comparison

BPC-157 Studied Golfer's Elbow: Research vs Clinical Reality Comparison

Dosage 10–20 mcg/kg body weight (rat studies) 200–500 mcg daily (human equivalent calculation) No pharmacokinetic data in humans. Dosing is extrapolated Dosing remains speculative…

Continue reading

Related articles